These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 14592851

  • 1. Decreased macrophage paraoxonase 2 expression in patients with hypercholesterolemia is the result of their increased cellular cholesterol content: effect of atorvastatin therapy.
    Rosenblat M, Hayek T, Hussein K, Aviram M.
    Arterioscler Thromb Vasc Biol; 2004 Jan; 24(1):175-80. PubMed ID: 14592851
    [Abstract] [Full Text] [Related]

  • 2. Urokinase plasminogen activator upregulates paraoxonase 2 expression in macrophages via an NADPH oxidase-dependent mechanism.
    Fuhrman B, Khateeb J, Shiner M, Nitzan O, Karry R, Volkova N, Aviram M.
    Arterioscler Thromb Vasc Biol; 2008 Jul; 28(7):1361-7. PubMed ID: 18436804
    [Abstract] [Full Text] [Related]

  • 3. Antioxidant effect of atorvastatin is independent of PON1 gene T(-107)C, Q192R and L55M polymorphisms in hypercholesterolaemic patients.
    Sardo MA, Campo S, Bonaiuto M, Bonaiuto A, Saitta C, Trimarchi G, Castaldo M, Bitto A, Cinquegrani M, Saitta A.
    Curr Med Res Opin; 2005 May; 21(5):777-84. PubMed ID: 15969877
    [Abstract] [Full Text] [Related]

  • 4. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE, Feely J, Sigurdsson EL, DISCOVERY study group.
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [Abstract] [Full Text] [Related]

  • 5. A biphasic U-shape effect of cellular oxidative stress on the macrophage anti-oxidant paraoxonase 2 (PON2) enzymatic activity.
    Shiner M, Fuhrman B, Aviram M.
    Biochem Biophys Res Commun; 2006 Oct 27; 349(3):1094-9. PubMed ID: 16970920
    [Abstract] [Full Text] [Related]

  • 6. Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation.
    Wissing KM, Unger P, Ghisdal L, Broeders N, Berkenboom G, Carpentier Y, Abramowicz D.
    Transplantation; 2006 Sep 27; 82(6):771-8. PubMed ID: 17006324
    [Abstract] [Full Text] [Related]

  • 7. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
    Lee SH, Chung N, Kwan J, Kim DI, Kim WH, Kim CJ, Kim HS, Park SH, Seo HS, Shin DG, Shin YW, Shim WJ, Ahn TH, Ho Yun K, Yoon MH, Cha KS, Choi SW, Han SW, Hyon MS.
    Clin Ther; 2007 Nov 27; 29(11):2365-73. PubMed ID: 18158077
    [Abstract] [Full Text] [Related]

  • 8. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
    Fonseca FA, Ruiz A, Cardona-Muñoz EG, Silva JM, Fuenmayor N, Marotti M, DISCOVERY PENTA investigators.
    Curr Med Res Opin; 2005 Aug 27; 21(8):1307-15. PubMed ID: 16083541
    [Abstract] [Full Text] [Related]

  • 9. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S.
    Clin Ther; 2008 Jun 27; 30(6):1089-101. PubMed ID: 18640465
    [Abstract] [Full Text] [Related]

  • 10. Macrophage paraoxonase 2 (PON2) expression is upregulated by unesterified cholesterol through activation of the phosphatidylinositol 3-kinase (PI3K) pathway.
    Shiner M, Fuhrman B, Aviram M.
    Biol Chem; 2007 Dec 27; 388(12):1353-8. PubMed ID: 18020951
    [Abstract] [Full Text] [Related]

  • 11. Paraoxonase 2 (PON2) expression is upregulated via a reduced-nicotinamide-adenine-dinucleotide-phosphate (NADPH)-oxidase-dependent mechanism during monocytes differentiation into macrophages.
    Shiner M, Fuhrman B, Aviram M.
    Free Radic Biol Med; 2004 Dec 15; 37(12):2052-63. PubMed ID: 15544923
    [Abstract] [Full Text] [Related]

  • 12. Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial).
    Lloret R, Ycas J, Stein M, Haffner S, STARSHIP Study Group.
    Am J Cardiol; 2006 Sep 15; 98(6):768-73. PubMed ID: 16950182
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E, Stender S, Mata P, Sager P, Ponsonnet D, Melani L, Lipka L, Suresh R, Maccubbin D, Veltri E, Ezetimibe Study Group.
    Am Heart J; 2004 Sep 15; 148(3):447-55. PubMed ID: 15389231
    [Abstract] [Full Text] [Related]

  • 15. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, Blasetto JW, Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group.
    Clin Ther; 2004 Sep 15; 26(9):1388-99. PubMed ID: 15531001
    [Abstract] [Full Text] [Related]

  • 16. Atorvastatin increases expression of low-density lipoprotein receptor mRNA in human circulating mononuclear cells.
    Pocathikorn A, Taylor RR, Mamotte CD.
    Clin Exp Pharmacol Physiol; 2010 Apr 15; 37(4):471-6. PubMed ID: 19930424
    [Abstract] [Full Text] [Related]

  • 17. Atorvastatin effect on the distribution of high-density lipoprotein subfractions and human paraoxonase activity.
    Harangi M, Mirdamadi HZ, Seres I, Sztanek F, Molnár M, Kassai A, Derdák Z, Illyés L, Paragh G.
    Transl Res; 2009 Apr 15; 153(4):190-8. PubMed ID: 19304278
    [Abstract] [Full Text] [Related]

  • 18. Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.
    Winkler K, Weltzien P, Friedrich I, Schmitz H, Nickell HH, Hauck P, Hoffmann MM, Baumstark MW, Wieland H, März W.
    Exp Clin Endocrinol Diabetes; 2004 May 15; 112(5):241-7. PubMed ID: 15146369
    [Abstract] [Full Text] [Related]

  • 19. Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol.
    Bergheanu SC, Van Tol A, Dallinga-Thie GM, Liem A, Dunselman PH, Van der Bom JG, Jukema JW.
    Curr Med Res Opin; 2007 Sep 15; 23(9):2235-40. PubMed ID: 17692153
    [Abstract] [Full Text] [Related]

  • 20. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR, Gandhi S, Blasetto J, Heien H, Sasane R, Nelson SP.
    Am J Geriatr Pharmacother; 2007 Sep 15; 5(3):185-94. PubMed ID: 17996658
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.